Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | STAT1 | P42224 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KLK3 | P07288 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30041235 | 0.86 | TDP1 (0.54) | RAB9ASMN1; SMN2NPC1L3MBTL1STAT1 | |
| SCHEMBL701884 | 0.86 | TDP1 (0.54) | RAB9ASMN1; SMN2NPC1L3MBTL1STAT1 | |
| SCHEMBL10114288 | 0.86 | POLB (0.57) | RAB9ASMN1; SMN2NPC1L3MBTL1STAT1 | |
| SCHEMBL13356595 | 0.85 | RAB9A (0.51) | RAB9ASMN1; SMN2NPC1L3MBTL1STAT1 | |
| SCHEMBL23409078 | 0.83 | NPC1 (0.43) | RAB9ASMN1; SMN2NPC1L3MBTL1STAT1 | |
| SCHEMBL18645166 | 0.83 | L3MBTL1 (0.50) | RAB9ASMN1; SMN2NPC1L3MBTL1STAT1 | |
| SCHEMBL18644549 | 0.83 | GAA (0.50) | RAB9ASMN1; SMN2NPC1L3MBTL1STAT1 | |
| SCHEMBL27326882 | 0.82 | TAS1R3 (0.58) | RAB9ASMN1; SMN2NPC1L3MBTL1STAT1 | |
| SCHEMBL9181228 | 0.82 | TAS1R3 (0.58) | RAB9ASMN1; SMN2NPC1L3MBTL1STAT1 | |
| SCHEMBL13080228 | 0.81 | RAB9A (0.42) | RAB9ASMN1; SMN2NPC1L3MBTL1STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2025-04-10 | — | — | US | disclosed |
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-12-03 | — | — | US | disclosed |
| CN-110770226-B | Sulfoximine glycosidase inhibitors | 阿森纽荣股份公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | PROTEGO BIOPHARMA, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-06-09 | — | — | US | disclosed |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11261183-B2 | Sulfoximine glycosidase inhibitors | ASCENEURON SA (CH) | 2022-03-01 | — | — | US | disclosed |
| CN-110770226-A | Sulfoximine glycosidase inhibitors | 阿森纽荣股份公司 | 2020-02-07 | — | — | CN | disclosed |
| WO-2018153508-A2 | SULFOXIMINE GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2018-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287021-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | TTR, TTPA, TNNC1 | RAB9A 3065/4885SMN1; SMN2 68/4885NPC1 684/4885 |
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ENGASE, BACE1, GAA | RAB9A 1707/4885SMN1; SMN2 722/4885NPC1 2614/4885 |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | RAB9A 1707/4885SMN1; SMN2 722/4885NPC1 2614/4885 |
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | RAB9A 1641/4885SMN1; SMN2 669/4885NPC1 2286/4885 |
| US-11261183-B2 | Sulfoximine glycosidase inhibitors | ENGASE, BACE1, GAA | RAB9A 1707/4885SMN1; SMN2 722/4885NPC1 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.